Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 7Pancreatic Neoplasms 4Urinary Bladder Neoplasms 3Ovarian Neoplasms 3Hematologic Neoplasms 3Breast Neoplasms 3Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Skin Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

pembrolizumab 3Trastuzumab 2Nivolumab 2tucatinib 1regorafenib 1pertuzumab 1niraparib 1milademetan 1dostarlimab 1cobimetinib 1brigimadlin 1atezolizumab 1alectinib 1Vemurafenib 1Tomography, X-Ray Computed 1Ramucirumab 1Radiation 1Positron-Emission Tomography 1Paclitaxel 1Magnetic Resonance Imaging 1HhAntag691 1Fulvestrant 1Erlotinib Hydrochloride 1Clinical Trials, Phase II as Topic 1Carboplatin 1Brachytherapy 1Antibodies 1AZD9833 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × pertuzumab × Genitourinary × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡